REC 604b
Alternative Names: REC-604bLatest Information Update: 24 Mar 2022
At a glance
- Originator Jiangsu Recbio Technology
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cervical cancer; Genital warts
Most Recent Events
- 07 Jan 2022 Beijing ABZYMO Biosciences has multiple patents protection for methods to create different types of HPV L1 protein with H. polymorpha expression system, in relation to REC 604b, in China
- 07 Jan 2022 Preclinical trials in Cervical cancer (Prevention) in China (unspecified route) (Jiangsu Recbio Technology pipeline, March 2022)
- 07 Jan 2022 Preclinical trials in Genital warts (Prevention) in China (unspecified route) (Jiangsu Recbio Technology pipeline, March 2022)